A phase I study to evaluate the safety/tolerability and immunogenicity of V-930 in patients with cancers expressing HER-2 [human epidermal growth factor receptor-2] and/or CEA [carcinoembryonic antigen]

Trial Profile

A phase I study to evaluate the safety/tolerability and immunogenicity of V-930 in patients with cancers expressing HER-2 [human epidermal growth factor receptor-2] and/or CEA [carcinoembryonic antigen]

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2006

At a glance

  • Drugs V-930 (Primary)
  • Indications Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top